US · RNAZ
TransCode Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02109
- Website
- transcodetherapeutics.com
Price · as of 2024-12-31
$7.83
Market cap 8.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $1,759,296.00 | ||||
| 2022 | $294,940.81 | ||||
| 2023 | $645.88 | ||||
| 2024 | $43.96 |
AI valuation
Our deep-learning model estimates TransCode Therapeutics, Inc.'s (RNAZ) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $7.83
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RNAZ | TransCode Therapeutics, I… | $7.83 | 8.81M | — | — | — | — | -0.93 | -7.75 | — | -0.61 | — | -7.75 | 0.00% | — | — | 8866.96% | 369.89% | -268.85% | -0.02 | -584.07 | 2.56 | 2.10 | 0.36 | -9864.00% | — | -2624.00% | -85.33% | -4.81 | 315.50% | 0.00% | 0.00% | 22.07% | -0.63 | -0.74 | — | -17.50 |
| ACXP | Acurx Pharmaceuticals, In… | $1.50 | 2.38M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| APRE | Aprea Therapeutics, Inc. | $0.92 | 6.41M | +3,789% | +73% | — | — | -0.99 | 0.66 | 8.54 | 0.70 | — | 0.66 | -523.16% | -953.00% | -862.43% | -68.98% | 415.99% | -55.58% | 0.00 | — | 7.01 | 6.80 | 1.60 | -4051.00% | 15763.00% | 1061.00% | -105.72% | -4.03 | 394.27% | 0.00% | 0.00% | 9.68% | 0.70 | 0.74 | -6.66 | -17.99 |
| APVO | Aptevo Therapeutics Inc. | $7.32 | 6.85M | — | — | — | — | -0.03 | 0.15 | — | 0.14 | — | 0.15 | 0.00% | — | — | -284.28% | -3555.20% | -119.36% | 0.97 | — | 1.72 | 1.40 | 0.17 | -9623.00% | — | 10277.00% | -3391.13% | -3.83 | -3437.14% | 0.00% | 0.00% | 0.00% | 0.14 | 0.14 | — | -27.06 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| GLTO | Galecto, Inc. | $29.58 | 47.25M | — | — | — | — | -0.22 | 0.30 | — | 0.45 | — | 0.30 | 0.00% | — | — | -89.03% | -3844.56% | -77.45% | 0.00 | — | 14.07 | 12.58 | 0.67 | -4864.00% | — | -4955.00% | -396.40% | -15.56 | -3216.41% | 0.00% | 0.00% | 0.00% | 0.42 | 0.50 | — | -23.70 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| INAB | IN8bio, Inc. | $1.70 | 7.88M | — | — | — | — | -13.04 | 27.41 | — | -14.50 | — | 27.41 | 0.00% | — | — | -154.44% | -359.44% | -111.38% | 0.35 | — | 4.08 | 3.61 | 0.23 | -4300.00% | — | 131.00% | -6.11% | -7.83 | -286.41% | 0.00% | 0.00% | 0.00% | -12.84 | -16.11 | — | 24.43 |
| KPRX | Kiora Pharmaceuticals, In… | $2.09 | 7.69M | — | +228% | +440% | — | 3.50 | 0.49 | 0.79 | -2.48 | — | 0.49 | 100.00% | 28.19% | 22.47% | 22.56% | 205.59% | 14.32% | 0.00 | 210.31 | 4.94 | 4.56 | -0.66 | -10359.00% | — | -18949.00% | 67.95% | 1.42 | 613.83% | 0.00% | 0.00% | 11.02% | -3.14 | -1.65 | -0.88 | -3.17 |
| LYRA | Lyra Therapeutics, Inc. | $1.01 | 1.79M | +2,414% | +280% | — | — | -6.69 | 53.92 | 407.49 | -10.27 | -49.59 | 53.92 | 100.00% | -6280.83% | -6090.94% | -184.99% | -1017.13% | -89.43% | 2.97 | — | 3.41 | 3.21 | 0.10 | 1349.00% | -154.00% | 1243.00% | -11.57% | -5.54 | -763.78% | 0.00% | 0.00% | 1.72% | -6.42 | -8.55 | 403.45 | -5.91 |
| PHIO | Phio Pharmaceuticals Corp… | $1.14 | 12.27M | — | — | — | — | -0.14 | 0.22 | — | 0.59 | — | 0.22 | 0.00% | — | — | -114.83% | 1067.49% | -94.69% | 0.00 | — | 5.65 | 5.30 | 0.73 | -9805.00% | — | -3386.00% | -694.83% | -7.01 | 1027.89% | 0.00% | 0.00% | 0.10% | 0.59 | 0.61 | — | -38.36 |
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
- CEO
- Philippe Calais
- Employees
- 7
- Beta
- 1.56
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $7.83) − 1 = — (DCF, example).